ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute Ischemic Stroke

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, Feb. 18, 2025 -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days, according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 5 to 7 in Los Angeles.

Min Lou, M.D., Ph.D., from the Second Affiliated Hospital of Zhejiang University School of Medicine in China, and colleagues conducted a prospective, randomized trial at 26 stroke centers in China involving patients with clinical signs of AIS within 4.5 and 24 hours and salvageable tissue on perfusion imaging. Patients were randomly assigned to receive intravenous alteplase or standard medical treatment (186 participants in both groups). The primary outcome was a score of 0 or 1 on the modified Rankin scale at 90 days.

Less than 3 percent of patients underwent endovascular thrombectomy (three and seven in the alteplase and standard medical treatment groups, respectively). The researchers found that the percentage of patients achieving a primary outcome was 40.3 and 26.3 percent in the alteplase and standard medical treatment groups, respectively (relative rate, 1.40; 95 percent confidence interval, 1.05 to 1.87). Mortality at 90 days was 10.8 percent with both alteplase and standard medical treatment, while the incidence of symptomatic intracerebral hemorrhage was 3.8 and 0.5 percent, respectively, within 36 hours after randomization.

"We believe these findings mean more people may return to normal or near-normal lives after a stroke, even if they receive treatment later than originally thought beneficial," Lou said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords